Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery

Area of Science:

• Cardiovascular Research
• Pharmacology
• Biomedical Engineering

Background:

• Heart failure is a major U.S. clinical challenge with high treatment development costs.
• Numerous cardiovascular clinical trials targeting the cardiac sarcomere have yielded limited success.
• Incomplete understanding of drug interactions with cardiac physiology contributes to high trial failure rates.

Purpose of the Study:

• To review preclinical cardiovascular study techniques for sarcomere-targeting heart failure therapies.
• To analyze tradeoffs between mechanistic transparency and physiological fidelity in these techniques.
• To propose a comprehensive, bottom-up approach for rigorous, hypothesis-driven drug discovery.

Main Methods:

• Evaluation of preclinical techniques across multiple biological levels: atomic, molecular, fiber, whole heart, and whole organism.
• Comparative analysis of existing methodologies for sarcomere-targeting heart failure drug development.
• Synthesis of findings to advocate for an integrated, bottom-up research strategy.

Main Results:

• Preclinical techniques vary in their ability to provide mechanistic detail versus physiological relevance.
• A bottom-up approach offers a more integrated and scientifically rigorous framework.
• Current drug discovery culture and clinical definitions may impede novel therapy development.

Conclusions:

• A hypothesis-driven, bottom-up approach to preclinical cardiovascular studies is crucial for developing effective heart failure treatments.
• Successful novel therapy development necessitates complementary changes in clinical definitions and drug discovery culture.
• Implementing this integrated strategy will improve the success rate of novel heart failure therapies.